TY - JOUR
T1 - Consensus classification of posterior cortical atrophy
AU - Alzheimer's Association ISTAART Atypical Alzheimer's Disease and Associated Syndromes Professional Interest Area
AU - Schott, Jonathan M.
AU - Lehmann, Manja
AU - Primativo, Silvia
AU - Rossor, Martin N.
AU - Ryan, Natalie S.
AU - Shakespeare, Timothy J.
AU - Suárez González, Aida
AU - Yong, Keir X.X.
AU - Fox, Nick C.
AU - Crutch, Sebastian J.
AU - Lehmann, Manja
AU - Murray, Melissa
AU - Snowden, Julie S.
AU - Snowden, Julie S.
AU - van der Flier, Wiesje M.
AU - Pijnenburg, Yolande
AU - Scheltens, Philip
AU - van der Flier, Wiesje M.
AU - Dickerson, Bradford C.
AU - Vandenberghe, Rik
AU - Ahmed, Samrah
AU - Butler, Christopher
AU - Bak, Thomas H.
AU - Boeve, Bradley F.
AU - Graff-Radford, Jonathan
AU - Cappa, Stefano F.
AU - Ceccaldi, Mathieu
AU - de Souza, Leonardo Cruz
AU - Dubois, Bruno
AU - Felician, Olivier
AU - Felician, Olivier
AU - Galasko, Douglas
AU - Graff-Radford, Neill R.
AU - Hof, Patrick R.
AU - Hof, Patrick R.
AU - Krolak-Salmon, Pierre
AU - Magnin, Eloi
AU - Mendez, Mario F.
AU - Nestor, Peter J.
AU - Onyike, Chiadi U.
AU - Pelak, Victoria S.
AU - Pelak, Victoria S.
AU - Suárez González, Aida
AU - Tang-Wai, David F.
AU - Carrillo, Maria
N1 - Funding Information:
This work was supported by the Alzheimer's Association and the International Society to Advance Alzheimer's Research and Treatment (ISTAART) Atypical Alzheimer's Disease and Associated Syndromes Professional Interest Area. The authors are grateful to Prof. Janice Holton, Dr. Tammaryn Lashley, and the Queen Square Brain Bank for providing Fig. 1. S.J.C. is supported by grants from ESRC/NIHR (ES/L001810/1), EPSRC (EP/M006093/1), and an Alzheimer's Research UK Senior Research Fellowship. C.B. is supported by the MRC (fellowship MR/K010395/1). S.A. is supported by the NIHR Oxford Biomedical Research Centre. D.G. is supported by NIH grant AG005131. C.U.O. is supported by NIH grant P50AG05146, the Jane Tanger Black Scholarship for Young-Onset Dementias, and the Nancy H. Hall Memorial Fund for Geriatric Psychiatry. P.H.R. is supported by NIH grant P50 AG005138. J.M.S. acknowledges the support of the NIHR Queen Square Dementia BRU, the NIHR UCL/H Biomedical Research Centre, Wolfson Foundation, EPSRC (EP/J020990/1), MRC (CSUB19166), ARUK (ARUK-Network 2012-6-ICE; ARUK-PG2014-1946), Brain Research Trust (UCC14191), and European Union's Horizon 2020 research and innovation program (grant 666992). N.S.R. is supported by a Brain Exit Fellowship. G.D.R. is supported by NIH grants R01-AG045611, P50-AG023501, U54-NS092089, R01-AG038791, and R01-AG048234, the Alzheimer's Association, American College of Radiology, Tau Consortium, Association for Frontotemporal Degeneration, and Michael J. Fox Foundation. T.J.S. is funded by an Alzheimer's Research UK Fellowship (ARUK-RF2013-5).
Funding Information:
This work was supported by the Alzheimer's Association and the International Society to Advance Alzheimer's Research and Treatment (ISTAART) Atypical Alzheimer's Disease and Associated Syndromes Professional Interest Area. The authors are grateful to Prof. Janice Holton, Dr. Tammaryn Lashley, and the Queen Square Brain Bank for providing Fig.?1. S.J.C. is supported by grants from ESRC/NIHR (ES/L001810/1), EPSRC (EP/M006093/1), and an Alzheimer's Research UK Senior Research Fellowship. C.B. is supported by the MRC (fellowship MR/K010395/1). S.A. is supported by the NIHR Oxford Biomedical Research Centre. D.G. is supported by NIH grant AG005131. C.U.O. is supported by NIH grant P50AG05146, the Jane Tanger Black Scholarship for Young-Onset Dementias, and the Nancy H. Hall Memorial Fund for Geriatric Psychiatry. P.H.R. is supported by NIH grant P50 AG005138. J.M.S. acknowledges the support of the NIHR Queen Square Dementia BRU, the NIHR UCL/H Biomedical Research Centre, Wolfson Foundation, EPSRC (EP/J020990/1), MRC (CSUB19166), ARUK (ARUK-Network 2012-6-ICE; ARUK-PG2014-1946), Brain Research Trust (UCC14191), and European Union's Horizon 2020 research and innovation program (grant 666992). N.S.R. is supported by a Brain Exit Fellowship. G.D.R. is supported by NIH grants R01-AG045611, P50-AG023501, U54-NS092089, R01-AG038791, and R01-AG048234, the Alzheimer's Association, American College of Radiology, Tau Consortium, Association for Frontotemporal Degeneration, and Michael J. Fox Foundation. T.J.S. is funded by an Alzheimer's Research UK Fellowship (ARUK-RF2013-5).
Publisher Copyright:
© 2017 The Authors
PY - 2017/8
Y1 - 2017/8
N2 - Introduction A classification framework for posterior cortical atrophy (PCA) is proposed to improve the uniformity of definition of the syndrome in a variety of research settings. Methods Consensus statements about PCA were developed through a detailed literature review, the formation of an international multidisciplinary working party which convened on four occasions, and a Web-based quantitative survey regarding symptom frequency and the conceptualization of PCA. Results A three-level classification framework for PCA is described comprising both syndrome- and disease-level descriptions. Classification level 1 (PCA) defines the core clinical, cognitive, and neuroimaging features and exclusion criteria of the clinico-radiological syndrome. Classification level 2 (PCA-pure, PCA-plus) establishes whether, in addition to the core PCA syndrome, the core features of any other neurodegenerative syndromes are present. Classification level 3 (PCA attributable to AD [PCA-AD], Lewy body disease [PCA-LBD], corticobasal degeneration [PCA-CBD], prion disease [PCA-prion]) provides a more formal determination of the underlying cause of the PCA syndrome, based on available pathophysiological biomarker evidence. The issue of additional syndrome-level descriptors is discussed in relation to the challenges of defining stages of syndrome severity and characterizing phenotypic heterogeneity within the PCA spectrum. Discussion There was strong agreement regarding the definition of the core clinico-radiological syndrome, meaning that the current consensus statement should be regarded as a refinement, development, and extension of previous single-center PCA criteria rather than any wholesale alteration or redescription of the syndrome. The framework and terminology may facilitate the interpretation of research data across studies, be applicable across a broad range of research scenarios (e.g., behavioral interventions, pharmacological trials), and provide a foundation for future collaborative work.
AB - Introduction A classification framework for posterior cortical atrophy (PCA) is proposed to improve the uniformity of definition of the syndrome in a variety of research settings. Methods Consensus statements about PCA were developed through a detailed literature review, the formation of an international multidisciplinary working party which convened on four occasions, and a Web-based quantitative survey regarding symptom frequency and the conceptualization of PCA. Results A three-level classification framework for PCA is described comprising both syndrome- and disease-level descriptions. Classification level 1 (PCA) defines the core clinical, cognitive, and neuroimaging features and exclusion criteria of the clinico-radiological syndrome. Classification level 2 (PCA-pure, PCA-plus) establishes whether, in addition to the core PCA syndrome, the core features of any other neurodegenerative syndromes are present. Classification level 3 (PCA attributable to AD [PCA-AD], Lewy body disease [PCA-LBD], corticobasal degeneration [PCA-CBD], prion disease [PCA-prion]) provides a more formal determination of the underlying cause of the PCA syndrome, based on available pathophysiological biomarker evidence. The issue of additional syndrome-level descriptors is discussed in relation to the challenges of defining stages of syndrome severity and characterizing phenotypic heterogeneity within the PCA spectrum. Discussion There was strong agreement regarding the definition of the core clinico-radiological syndrome, meaning that the current consensus statement should be regarded as a refinement, development, and extension of previous single-center PCA criteria rather than any wholesale alteration or redescription of the syndrome. The framework and terminology may facilitate the interpretation of research data across studies, be applicable across a broad range of research scenarios (e.g., behavioral interventions, pharmacological trials), and provide a foundation for future collaborative work.
KW - Alzheimer's disease
KW - Biomarker
KW - Clinico-radiological syndrome
KW - Pathophysiology
KW - Posterior cortical atrophy
UR - http://www.scopus.com/inward/record.url?scp=85016060093&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016060093&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2017.01.014
DO - 10.1016/j.jalz.2017.01.014
M3 - Article
C2 - 28259709
AN - SCOPUS:85016060093
SN - 1552-5260
VL - 13
SP - 870
EP - 884
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 8
ER -